These Analysts Cut Their Forecasts On uniQure Following Q4 Results - uniQure (NASDAQ:QURE)

Core Insights - uniQure N.V. reported a narrower quarterly loss of 56 cents per share, outperforming the analyst consensus estimate of 94 cents per share [1] - The company achieved quarterly sales of $5.568 million, exceeding the analyst consensus estimate of $5.204 million [1] FDA Guidance - The FDA advised against using Phase 1/2 study data as primary evidence for the marketing application of AMT-130, a gene therapy for Huntington's disease [2] - The FDA recommended that uniQure conduct a prospective, randomized, double-blind, sham surgery-controlled study to proceed with the application [2] Stock Performance and Analyst Reactions - Following the earnings announcement and FDA guidance, uniQure shares fell by 13.3%, trading at $9.12 [2] - Mizuho analyst downgraded uniQure from Outperform to Neutral, lowering the price target from $33 to $12 [3] - Chardan Capital analyst maintained a Buy rating but reduced the price target from $53 to $16 [3]